26 related articles for article (PubMed ID: 21372498)
1. Exosomal miR-493 suppresses MAD2L1 and induces chemoresistance to intraperitoneal paclitaxel therapy in gastric cancer patients with peritoneal metastasis.
Makinoya M; Miyatani K; Matsumi Y; Sakano Y; Shimizu S; Shishido Y; Hanaki T; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Saito H; Nakayama Y; Osaki M; Okada F; Fujiwara Y
Sci Rep; 2024 May; 14(1):10075. PubMed ID: 38698201
[TBL] [Abstract][Full Text] [Related]
2. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
Rudloff U; Langan RC; Mullinax JE; Beane JD; Steinberg SM; Beresnev T; Webb CC; Walker M; Toomey MA; Schrump D; Pandalai P; Stojadinovic A; Avital I
J Surg Oncol; 2014 Sep; 110(3):275-84. PubMed ID: 25042700
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis.
Imano M; Yasuda A; Itoh T; Satou T; Peng YF; Kato H; Shinkai M; Tsubaki M; Chiba Y; Yasuda T; Imamoto H; Nishida S; Takeyama Y; Okuno K; Furukawa H; Shiozaki H
J Gastrointest Surg; 2012 Dec; 16(12):2190-6. PubMed ID: 23099736
[TBL] [Abstract][Full Text] [Related]
4. A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis.
Imano M; Peng YF; Itoh T; Nishikawa M; Satou T; Yasuda A; Inoue K; Kato H; Shinkai M; Tsubaki M; Yasuda T; Imamoto H; Nishida S; Furukawa H; Takeyama Y; Okuno K; Shiozaki H
Anticancer Res; 2012 Sep; 32(9):4071-5. PubMed ID: 22993363
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.
Yang XJ; Huang CQ; Suo T; Mei LJ; Yang GL; Cheng FL; Zhou YF; Xiong B; Yonemura Y; Li Y
Ann Surg Oncol; 2011 Jun; 18(6):1575-81. PubMed ID: 21431408
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer.
Zhao S; Su L; Chen Y; Li X; Lin P; Chen W; Fang W; Zhu J; Li H; Ren L; Liu J; Hong Y; Lin S; Fan N; Lin R
Front Oncol; 2022; 12():850242. PubMed ID: 36158665
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis.
Kobayashi D; Kodera Y
Gastric Cancer; 2017 Mar; 20(Suppl 1):111-121. PubMed ID: 27803990
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.
Hasovits C; Clarke S
Clin Pharmacokinet; 2012 Apr; 51(4):203-24. PubMed ID: 22420577
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y
Oncology; 2020; 98(1):48-52. PubMed ID: 31487733
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
[TBL] [Abstract][Full Text] [Related]
11. Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes.
Yamaguchi H; Kitayama J; Ishigami H; Kazama S; Nozawa H; Kawai K; Hata K; Kiyomatsu T; Tanaka T; Tanaka J; Nishikawa T; Otani K; Yasuda K; Ishihara S; Sunami E; Watanabe T
World J Gastrointest Oncol; 2015 Nov; 7(11):285-91. PubMed ID: 26600928
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal infusion of paclitaxel with S-1 for peritoneal metastasis of advanced gastric cancer: phase I study.
Kurita N; Shimada M; Iwata T; Nishioka M; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T; Nakao T
J Med Invest; 2011 Feb; 58(1-2):134-9. PubMed ID: 21372498
[TBL] [Abstract][Full Text] [Related]
13. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer.
Ishigami H; Kitayama J; Otani K; Kamei T; Soma D; Miyato H; Yamashita H; Hidemura A; Kaisaki S; Nagawa H
Oncology; 2009; 76(5):311-4. PubMed ID: 19299904
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
Yamaguchi H; Kitayama J; Ishigami H; Emoto S; Yamashita H; Watanabe T
Cancer; 2013 Sep; 119(18):3354-8. PubMed ID: 23798046
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
